Growth Metrics

Oruka Therapeutics (ORKA) Total Current Liabilities (2010 - 2026)

Oruka Therapeutics' quarterly Total Current Liabilities came in at $16.6 million in Q1 2026, up 41.88% year-on-year from $11.7 million in Q1 2025, and up 8.19% quarter-over-quarter from $15.4 million in Q4 2025.

Oruka Therapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $16.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Total Current Liabilities rose 41.88% year-over-year to $16.6 million; the trailing twelve-month figure through Mar 2026 stood at $16.6 million (up 41.88% YoY), and the FY2025 full-year result was $15.4 million, up 17.87% from the prior year.
  • Total Current Liabilities for Q1 2026 stood at $16.6 million, up from $15.4 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $21.0 million in Q3 2025, with the low at $637000.0 in Q4 2023.
  • Average Total Current Liabilities over 5 years is $7.3 million, with a median of $2.7 million recorded in 2022.
  • Year-over-year, Total Current Liabilities plunged 67.64% in 2022 and surged 1947.57% in 2024.
  • Tracing ORKA's Total Current Liabilities over 5 years: stood at $1.1 million in 2022, then plunged by 43.73% to $637000.0 in 2023, then surged by 1947.57% to $13.0 million in 2024, then rose by 17.87% to $15.4 million in 2025, then increased by 8.19% to $16.6 million in 2026.
  • The last three Total Current Liabilities figures came in at $16.6 million (Q1 2026), $15.4 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 16.35 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1.70 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 636.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 66.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 13.42 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 3.88 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 5.11 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.35 Bn
10 Oruka Therapeutics 3.04 Bn 2.65 Bn - 16.63 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 16.63 Mn
Dec 31, 2025 15.37 Mn
Sep 30, 2025 20.97 Mn
Jun 30, 2025 12.11 Mn
Mar 31, 2025 11.72 Mn
Dec 31, 2024 13.04 Mn
Sep 30, 2024 18.04 Mn
Jun 30, 2024 1.27 Mn
Mar 31, 2024 1.58 Mn
Dec 31, 2023 637,000.00
Sep 30, 2023 992,000.00
Jun 30, 2023 1.60 Mn
Mar 31, 2023 1.27 Mn
Dec 31, 2022 1.13 Mn
Sep 30, 2022 1.94 Mn
Jun 30, 2022 2.81 Mn
Mar 31, 2022 2.72 Mn
Dec 31, 2021 3.50 Mn
Sep 30, 2021 3.18 Mn
Jun 30, 2021 3.70 Mn
Mar 31, 2021 2.88 Mn
Dec 31, 2020 3.50 Mn
Sep 30, 2020 1.53 Mn
Jun 30, 2020 1.33 Mn
Mar 31, 2020 1.16 Mn
Dec 31, 2019 926,000.00
Sep 30, 2019 1.15 Mn
Jun 30, 2019 1.20 Mn
Mar 31, 2019 1.29 Mn
Dec 31, 2018 793,000.00
Sep 30, 2018 978,000.00
Jun 30, 2018 1.06 Mn
Mar 31, 2018 1.72 Mn
Dec 31, 2017 2.07 Mn
Sep 30, 2017 2.54 Mn
Jun 30, 2017 2.52 Mn
Mar 31, 2017 2.52 Mn
Dec 31, 2016 2.40 Mn
Sep 30, 2016 2.16 Mn
Jun 30, 2016 1.70 Mn
Mar 31, 2016 2.34 Mn
Dec 31, 2015 1.50 Mn
Sep 30, 2015 1.30 Mn
Jun 30, 2015 1.36 Mn
Mar 31, 2015 1.13 Mn
Dec 31, 2014 1.39 Mn
Sep 30, 2014 838,000.00
Jun 30, 2014 1.22 Mn
Mar 31, 2014 1.12 Mn
Dec 31, 2013 1.50 Mn
Sep 30, 2013 769,000.00
Jun 30, 2013 750,000.00
Mar 31, 2013 828,000.00
Dec 31, 2012 305,000.00
Sep 30, 2012 286,000.00
Jun 30, 2012 529,000.00
Mar 31, 2012 594,000.00
Dec 31, 2011 754,000.00
Sep 30, 2011 661,000.00
Jun 30, 2011 1.00 Mn
Dec 31, 2010 1.19 Mn